Literature DB >> 6959532

Totally implanted system for intravenous chemotherapy in patients with cancer.

J Gyves, W Ensminger, J Niederhuber, M Liepman, E Cozzi, K Doan, S Dakhil, R Wheeler.   

Abstract

A totally implanted system for improved central venous access has been investigated in 20 patients with cancer (six with solid tumors, four with leukemia, and 10 with lymphomas) who were treated with aggressive chemotherapy regimens and who lacked peripheral venous sites. The system is implanted using local anesthesia and consists of a subcutaneous injection port connected to a Silastic catheter threaded through the subclavian vein into the superior vena cava. Injections and continuous infusions (for up to three weeks) of virtually all classes of antineoplastic agents, antibiotics, blood components, and intravenous solutions were administered through the system. The system was filled with heparinized saline and not otherwise flushed between uses. The system has remained functional for periods exceeding 450 days (mean 235 days). There was no significant local irritation and no system became infected. None of 18 large-bore catheters (0.63 mm lumen) became occluded (seven to 300 days), whereas five of six small-bore catheters (0.38 mm lumen) became occluded (90 to 420 days). Three of the occluded systems were replaced. Acceptance has been excellent, and patients have had no impediment to normal activities. This system appears to be an alternate means of safe and reliable central venous access with improved convenience and cosmetic acceptability.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959532     DOI: 10.1016/0002-9343(82)90774-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Persistent left superior vena cava: a reason for pseudodisplacement of a port catheter.

Authors:  L Schiffmann; M Kruschewski; F Wacker; H J Buhr
Journal:  Surg Radiol Anat       Date:  2003-04-03       Impact factor: 1.246

2.  Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients.

Authors:  M A de Gregorio; J M Miguelena; J A Fernández; C de Gregorio; A Tres; E R Alfonso
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

3.  Retrospective outcome analysis of rates and types of complications after 8654 minimally invasive radiological port implantations via the subclavian vein without ultrasound guidance.

Authors:  Karolin J Paprottka; Jana Voelklein; Tobias Waggershauser; Maximilian F Reiser; Philipp M Paprottka
Journal:  Radiol Med       Date:  2019-06-07       Impact factor: 3.469

4.  [A totally implantable permanent central venous access, long-term experience with subcutaneous infusion chambers].

Authors:  M Lorenz; C Hottenrott; R M Seufert; A Encke
Journal:  Langenbecks Arch Chir       Date:  1988

5.  [Indications, technique and complications of port implantation].

Authors:  L Haeder; J Jähne
Journal:  Chirurg       Date:  2013-07       Impact factor: 0.955

6.  [The Huber needle as a special cannula for the puncture of implanted ports and pumps--a mistake in multiple variations].

Authors:  H Müller; J Zierski
Journal:  Klin Wochenschr       Date:  1988-10-03

7.  Comparison between peripherally implanted ports and externally sited catheters for long-term venous access.

Authors:  A M Pullyblank; P D Carey; S Z Pearce; A G Tanner; P J Guillou; J R Monson
Journal:  Ann R Coll Surg Engl       Date:  1994-01       Impact factor: 1.891

Review 8.  Hepatic Arterial Infusion Pump: Complications and Nursing Management Regarding Use in Patients With Colorectal Cancer.

Authors:  Deborah Italiano
Journal:  Clin J Oncol Nurs       Date:  2018-06-01       Impact factor: 1.027

9.  Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system.

Authors:  Y Arai; T Endo; Y Sone; N Tohyama; Y Inaba; S Kohno; Y Ariyoshi; C Kido
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Implantable subcutaneous infusion ports.

Authors:  L T Soh; P T Ang
Journal:  Support Care Cancer       Date:  1993-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.